Teva pharmaceuticals news

Teva announced several organizational changes, including naming Sigurdur Olafsson as the president and CEO of its newly created Global Generic Medicines group. Olafsson was president of the pharma segment at Actavis plc (NYSE:ACT, Dublin, Ireland). The group will be responsible for Teva's generic and OTC businesses.

Last year, Teva created a Global Specialty Medicines group headed by Rob Koremans to accelerate worldwide launches of branded specialty products. Teva said its branded and generic R&D will remain under one roof and that there are no changes to Michael Hayden's role as CSO and president of global R&D (see BioCentury, April 29, 2013). ...